LIONESS OF JUDAH MINISTRY: "Dr. Mike Yeadon Comments on “COVID mRNA Vaccine-Associated Mortality in the Southern Hemisphere” by Denis Rancourt "It really is devastating...To my knowledge, no one

has rebutted any of his reports." Excellent scholarship by Yeadon! Rancourt is stellar & over the target! It really is devastating. paper more accurately quantifies that burden of deaths due to shots

Dr. Mike Yeadon Comments on “COVID-19 Vaccine-Associated Mortality in the Southern Hemisphere” by Denis Rancourt

By Dr. Michael Yeadon September 21, 2023

The latest paper by Denis Rancourt and colleagues.

It really is devastating.

While not a new idea of course - that these gene-based injections injure & kill was likely to some of us from the period before emergency use authorization.

This paper more accurately quantifies that burden of deaths directly caused by these jabs.

To my knowledge, no one has rebutted any of his reports. Plenty of criticism, but no specifics. Some of the discussion is copied below.

Best wishes,

Mike

Synchronicity between the many peaks in ACM (in 17 countries, on 4 continents, in all elderly age groups, at different times) and associated rapid booster rollouts allows this 2

Firm conclusion regarding causality, and accurate quantification of COVID-19-vaccine toxicity.

The all-ages vaccine-dose fatality rate (vDFR), which is the ratio of inferred vaccine- induced deaths to vaccine doses delivered in a population, is quantified for the January- February 2022 ACM peak to fall in the range 0.02 % (New Zealand) to 0.20 % (Uruguay).

In Chile and Peru, the vDFR increases exponentially with age (doubling approximately every 4 years of age), and is largest for the latest booster doses, reaching approximately 5 % in the 90+ years age groups (1 death per 20 injections of dose 4). Comparable results occur for the Northern Hemisphere, as found in previous articles (India, Israel, USA).

We quantify the overall all-ages vDFR for the 17 countries to be (0.126 ± 0.004) %, which would imply 17.0 ± 0.5 million COVID-19 vaccine deaths worldwide, from 13.50 billion injections up to 2 September 2023.

This would correspond to a mass iatrogenic event that killed (0.213 ± 0.006) % of the world population (1 death per 470 living persons, in less than 3 years), and did not measurably prevent any deaths.

Download PDF

Abstract

‘Seventeen equatorial and Southern-Hemisphere countries were studied (Argentina, Australia, Bolivia, Brazil, Chile, Colombia, Ecuador, Malaysia, New Zealand, Paraguay, Peru, Philippines, Singapore, South Africa, Suriname, Thailand, Uruguay), which comprise 9.10 % of worldwide population, 10.3 % of worldwide COVID-19 injections (vaccination rate of 1.91 injections per person, all ages), virtually every COVID-19 vaccine type and manufacturer, and span 4 continents. 2

In the 17 countries, there is no evidence in all-cause mortality (ACM) by time data of any beneficial effect of COVID-19 vaccines. There is no association in time between COVID-19 vaccination and any proportionate reduction in ACM. The opposite occurs.

All 17 countries have transitions to regimes of high ACM, which occur when the COVID-19 vaccines are deployed and administered. Nine of the 17 countries have no detectable excess ACM in the period of approximately one year after a pandemic was declared on 11 March 2020 by the World Health Organization (WHO), until the vaccines are rolled out (Australia, Malaysia, New Zealand, Paraguay, Philippines, Singapore, Suriname, Thailand, Uruguay).

Unprecedented peaks in ACM occur in the summer (January-February) of 2022 in the Southern Hemisphere, and in equatorial-latitude countries, which are synchronous with or immediately preceded by rapid COVID-19-vaccine-booster-dose rollouts (3rd or 4th doses). This phenomenon is present in every case with sufficient mortality data (15 countries). Two of the countries studied have insufficient mortality data in JanuaryFebruary 2022 (Argentina and Suriname).

Detailed mortality and vaccination data for Chile and Peru allow resolution by age and by dose number. It is unlikely that the observed peaks in all-cause mortality in JanuaryFebruary 2022 (and additionally in: July-August 2021, Chile; July-August 2022, Peru), in each of both countries and in each elderly age group, could be due to any cause other than the temporally associated rapid COVID-19-vaccine-booster-dose rollouts.

Likewise, it is unlikely that the transitions to regimes of high ACM, coincident with the rollout and sustained administration of COVID-19 vaccines, in all 17 SouthernHemisphere and equatorial-latitude countries, could be due to any cause other than the vaccines. Synchronicity between the many peaks in ACM (in 17 countries, on 4 continents, in all elderly age groups, at different times) and associated rapid booster rollouts allows this 3 firm conclusion regarding causality, and accurate quantification of COVID-19-vaccine toxicity.

The all-ages vaccine-dose fatality rate (vDFR), which is the ratio of inferred vaccineinduced deaths to vaccine doses delivered in a population, is quantified for the JanuaryFebruary 2022 ACM peak to fall in the range 0.02 % (New Zealand) to 0.20 % (Uruguay). In Chile and Peru, the vDFR increases exponentially with age (doubling approximately every 4 years of age), and is largest for the latest booster doses, reaching approximately 5 % in the 90+ years age groups (1 death per 20 injections of dose 4).

Comparable results occur for the Northern Hemisphere, as found in previous articles (India, Israel, USA). We quantify the overall all-ages vDFR for the 17 countries to be (0.126 ± 0.004) %, which would imply 17.0 ± 0.5 million COVID-19 vaccine deaths worldwide, from 13.50 billion injections up to 2 September 2023. This would correspond to a mass iatrogenic event that killed (0.213 ± 0.006) % of the world population (1 death per 470 living persons, in less than 3 years), and did not measurably prevent any deaths.

The overall risk of death induced by injection with the COVID-19 vaccines in actual populations, inferred from excess all-cause mortality and its synchronicity with rollouts, is globally pervasive and much larger than reported in clinical trials, adverse effect monitoring, and cause-of-death statistics from death certificates, by 3 orders of magnitude (1,000-fold greater). The large age dependence and large values of vDFR quantified in this study of 17 countries on 4 continents, using all the main COVID-19 vaccine types and manufacturers, should induce governments to immediately end the baseless public health policy of prioritizing elderly residents for injection with COVID-19 vaccines, until valid risk-benefit analyses are made.’